Research letterVitiligo under anti–programmed cell death-1 therapy is associated with increased survival in melanoma patients
References (5)
- et al.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Lancet Oncol
(2015) - et al.
Immune-related adverse events associated with immune checkpoint blockade
N Engl J Med
(2018 11)
Cited by (22)
Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
2021, JAAD InternationalCitation Excerpt :It was important to avoid a selection bias because patients in whom vitiligo develops may receive the treatment for long enough and live long enough for skin irAEs to develop. These findings are of clinical relevance because the association of vitiligo with increased survival is still debated, mainly due to the low number of patients reported.4-6,14,15 The incidence of vitiligo in patients treated with anti–PD-1 therapies was estimated to be 18.6%, similar to that found in a previous prospective real-life study.5
SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the Wnt/β-catenin signaling
2021, Genes and DiseasesCitation Excerpt :Furthermore, the mRNA and protein expression of SFRP5 was significantly increased in PIG3V cells compared with that in PIG1 cells. Emerging evidences highlight that vitiligo has an inverse relationship with malignant melanoma,52–56 which is consistent with our results. The formation and maturation of melanosomes and the ability to synthesize melanin are key to vitiligo repigmentation.57,58
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology
2020, Journal of Investigative DermatologyImmunologic adverse events from immune checkpoint therapy
2020, Best Practice and Research: Clinical RheumatologyCitation Excerpt :In this setting, successful destruction of tumor cells leads to presentation of tumor-specific and non-specific melanocyte antigens to CD4+ and CD8+ T cells in draining lymph nodes (linked antigen presentation), which, in the presence of continued ICI therapy, generates new T cells responses against the tumor as well as healthy melanocytes [29,34,35]. Consistent with this idea, the development of vitiligo strongly predicts successful anti-melanoma responses [36,37]. A similar mechanism may also link some cases of pneumonitis to anti-tumor responses in patients with NSCLC [38].
Drs Nardin and Jeand'heur contributed equally to this article.
Drs Puzenat and Aubin contributed equally to this article.
Funding sources: None.
Conflicts of interest: Dr Nardin has been a consultant for Novartis, BMS, and MSD. All other authors have no conflicts of interest to declare.
IRB approval status: Reviewed and approved by the Direction de la Recherche Clinique et de l'Innovation (Besançon, France).